Table 1.

Patient baseline characteristics (n=13).

Patient characteristics at initiation of study treatment	N (%)
Male sex	11 (85%)
Median age, years (range)	68 (44–75)
Prior chemoimmunotherapy	8 (62%)
Median prior treatments (range)	1 (1–2)
• Prior purine analogue	9 (69%)
• Prior rituximab	10 (77%)
• Prior alemtuzumab	5 (38%)
• Chlorambucil	1 (7.7%)
Rai stage, median (range)	3 (1–4)
• Rai 1–2	5 (38%)
• Rai 3–4	8 (61%)
CLL FISH
• 11q-	4 (31%)
• Trisomy 12	2 (15%)
• 13q-	3 (23%)
• Normal	2 (15%)
• Other	2 (15%)
Median β-2 microglobulin (range)	7.11 (3.4–9.9)
IgHV status
• Unmutated	10 (77%)
• Mutated	1 (7.7%)
• Not done	2 (15%)
ZAP-70 expression
• Positive	8 (62%)
• Negative	3 (23%)
• Not done	2 (15%)
CD38 expression
• Positive	8 (46%)
• Negative	5 (23%)
Median ALC (×103/uL) (range)	43.9 (1.5 – 306.3)